Wall Street Zen has downgraded Home BancShares (NYSE:HOMB) to a "sell" rating from a "hold," despite the broader analyst consensus remaining a "Hold" with an average price target of $31.80. The downgrade follows Q1 results where EPS met expectations but revenue missed estimates. The stock is currently trading around $26.87, below its 50- and 200-day moving averages, and has seen recent insider selling though institutional investors hold a significant stake.

Wall Street Zen has downgraded Kimco Realty (NYSE:KIM) from "hold" to "sell." Despite this, the consensus analyst rating remains a "Moderate Buy" with an average target price of $24.73. Kimco Realty, which specializes in open-air shopping centers, currently trades near its one-year high and has a market capitalization of $16.3 billion.

Wall Street Zen has upgraded Information Services Group (NASDAQ:III) from "buy" to "strong-buy," although the MarketBeat consensus remains a "Hold" with a $5.50 price target. The company recently reported Q4 EPS of $0.08 and revenue of $61.21 million, both meeting estimates. Institutional ownership for ISG stands at 73.10%, with several funds significantly increasing their positions, indicating growing investor confidence.

Short interest in Helix Energy Solutions Group (NYSE:HLX) decreased by 15.1% in March, totaling 5,030,795 shares, which represents about 3.7% of the stock and a 2.6-day-to-cover ratio. The company recently reported better-than-expected earnings with EPS of $0.06 and revenue of $334.2 million, though revenue was down 5.9% year-over-year. Analysts currently hold a "Moderate Buy" rating for HLX with an average target price of $10.50.

Wall Street Zen has upgraded Interparfums (IPAR) stock rating from "hold" to "buy," aligning with MarketBeat's consensus of "Moderate Buy" and an average analyst target price of $110.67. The company recently surpassed quarterly earnings expectations with an EPS of $0.88 and revenue of $386.18 million, representing a 6.8% year-over-year increase. Despite CEO Jean Madar selling 20,000 shares, insiders still hold 43.7% of the company, and institutional investors own 55.6%.

Wall Street Zen downgraded ICU Medical (NASDAQ:ICUI) from "buy" to "hold." This comes after ICU Medical reported Q4 EPS of $1.91, exceeding estimates, but revenue of $535.9M missed expectations and was down 14.1% year-over-year. The medical instruments supplier has a mixed analyst outlook with an average rating of "Moderate Buy" and institutional ownership around 96%.

Wall Street Zen has upgraded Henry Schein (NASDAQ:HSIC) from a "buy" to a "strong-buy" rating. This upgrade follows Henry Schein beating quarterly expectations with an EPS of $1.34 and revenue of $3.44 billion, and setting strong FY2026 guidance. Despite the upgrade, analyst sentiment is mixed, with the company holding an average "Hold" rating from MarketBeat based on various analyst recommendations.

IDEAYA Biosciences (NASDAQ:IDYA) had its stock rating upgraded by Wall Street Zen from "sell" to "hold". This comes as the company beat its latest quarterly estimates for both EPS and revenue, with the stock trading near $33.91 and a market cap of $2.98 billion. Additionally, a director recently purchased a significant amount of shares, increasing his stake in the company.

Wall Street Zen has upgraded Motorola Solutions (NYSE:MSI) from a "hold" to a "buy" rating, aligning with a consensus "Buy" rating and an average price target of $502.50 from analysts. This upgrade follows strong Q4 earnings, where MSI exceeded expectations with $4.59 EPS and $3.38 billion in revenue, coupled with robust profitability metrics. Despite significant insider selling over the past 90 days, institutional investors are increasing their stakes in the company.

Wall Street Zen has upgraded iQIYI (NASDAQ:IQ) from a "sell" to a "hold" rating. The company now holds a consensus "Hold" rating and a target price of $2.55, following mixed analyst coverage including two Buys, one Hold, and one Sell. Institutional investors currently own about 52.7% of iQIYI shares, with notable recent purchases from firms like UBS and Marshall Wace.